SCHEMBL25819197

SCHEMBL25819197

Cc1cccc(-c2ccc(C)nc2OCc2ccccc2)c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 3/20 0.44
TP53 P04637 2/20 0.44
SQOR Q9Y6N5 1/20 0.44
MAOB P27338 1/20 0.44
ADORA1 P30542 1/20 0.43
PDE5A O76074 1/20 0.42
NPC1 O15118 2/20 0.41
RAB9A P51151 2/20 0.41
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
MAPT P10636 2/20 0.40
MAPK1 P28482 1/20 0.40
TDP1 Q9NUW8 1/20 0.40
ALDH1A1 P00352 1/20 0.40
GAA P10253 1/20 0.40
PKM P14618 1/20 0.40
HPGD P15428 1/20 0.40
ALOX12 P18054 1/20 0.40
CNR1 P21554 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30475448 0.88 L3MBTL1 (0.43) L3MBTL1TP53SQORMAOBADORA1
SCHEMBL25035166 0.88 L3MBTL1 (0.43) L3MBTL1TP53SQORMAOBADORA1
SCHEMBL25819100 0.88 L3MBTL1 (0.43) L3MBTL1SQORADORA1PDE5AMAPT
SCHEMBL25935014 0.87 GABRG2 (0.49) L3MBTL1SQORMAOBPDE5AMEN1
SCHEMBL25819126 0.81 L3MBTL1 (0.47) L3MBTL1SQORMAPTMAPK1ALDH1A1
SCHEMBL25819597 0.81 L3MBTL1 (0.42) L3MBTL1SQORMEN1KMT2ACNR1
SCHEMBL25482306 0.81 DYRK1A (0.44) L3MBTL1SQOR
SCHEMBL26043794 0.80 L3MBTL1 (0.46) L3MBTL1SQORPDE5ACNR1
SCHEMBL26044686 0.80 MEN1 (0.48) L3MBTL1SQORPDE5ANPC1RAB9A
SCHEMBL26043793 0.80 MAPT (0.47) L3MBTL1SQORMAOBRAB9ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11912710-B2 Substituted pyrimido[4,5-b][1,4]diazepines as PLK1 degradation inducers UPPTHERA, INC. (KR) 2024-02-27 US disclosed
US-20230219966-A1 NOVEL PLK1 DEGRADATION INDUCING COMPOUND UPPTHERA, INC. (KR) 2023-07-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230219966-A1 NOVEL PLK1 DEGRADATION INDUCING COMPOUND PLK1, BUB1B, BUB1 L3MBTL1 964/4885TP53 15/4885SQOR 3787/4885
US-11912710-B2 Substituted pyrimido[4,5-b][1,4]diazepines as PLK1 degradation inducers PLK1, BUB1B, BUB1 L3MBTL1 2040/4885TP53 74/4885SQOR 2802/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.